Robert Herpen

Vidofludimus calcium for relapsing-remitting MS was safe and well-tolerated in an open-label extension, with a high degree of treatment persistence, according to a poster presented at ECTRIMS 2025 in Barcelona. “Currently, progressive MS has very limited treatment options, and the limited options have safety concerns,” Robert Fox, MD, staff neurologist at the Mellen Center for

Focal treatment-resistant epilepsy improved in patients who had multiple medication failures, with added antiseizure medications contributing to seizure reduction within a 12-month follow-up, according to data published in JAMA Neurology.“About one-third of people who develop focal epilepsy will not respond to anti-seizure medication and will be considered treatment resistant,”

For older adults in the Netherlands, mental health in the period surrounding retirement was influenced by a number of factors, with income level being the most significant driver, data show.“Most studies on retirement and mental health have looked at broad retirement averages, overlooking the dynamic changes that occur across different phases of the transition,” Xuefei Li, PhD, from

Environmental exposure to trichloroethylene may increase the risk for developing Parkinson’s disease, particularly in heavily industrialized parts of the United States or within close range of production facilities. “Others have shared compelling evidence from studies of occupational trichloroethylene (TCE) exposure in factory workers but less is known about how TCE in neighborhood air pollution

The University of California, San Francisco, has received a gift of $100 million for its Memory and Aging Center, dedicated to research and development of tests and treatments for neurodegenerative conditions. “We applaud the Edward Fein Charitable Trust for their visionary support; this will accelerate the pace of research, education, and care for people with dementia,” UCSF Chancellor Sam

The FDA has approved a combination of doxecitine and doxribtimine to treat patients with thymidine kinase 2 deficiency for whom symptom onset occurred on or before age 12, according to the manufacturer. In a press release, UCB said Kygevvi is the first and only approved treatment for these patients living with the rare mitochondrial disorder, also known as TK2d.

The FDA has approved an adeno-associated virus 9 gene replacement therapy to treat individuals aged 2 years and older with spinal muscular atrophy and a confirmed mutation of the survival motor neuron 1 gene, according to the manufacturer.In a press release, Novartis said the FDA’s approval positions Itvisma (onasemnogene abeparvovec-brve) as the first and only gene replacement therapy

With the expectations of friends and family to squeeze a high degree of activity and socialization into a short period of time during the holidays, individuals with bipolar disorder may find it difficult to maintain their daily routines. Healio spoke to Roger Rivera, DNP, PMHNP, a family nurse practitioner and psychiatric–mental health nurse practitioner based in central Florida, to find

The question of whether invasive or noninvasive methods provide the best possible outcomes for patients with neurodegenerative conditions persists for researchers. A collaboration between Openwater Health, a San Francisco-based medical technology firm, and a Barcelona-based hospital seeks to provide a clear answer by conducting pilot trials with the former’s version of open low-intensity focused

SAN DIEGO — For individuals with MS, proteomic analysis offers insight into the role disease progression plays in affecting both biological and chronological age progression as well as mortality risk, according to a speaker at ACTRIMS. “We know that aging is the most important prognostic factor for MS because it drives the transition from relapsed-remaining MS to the progressive phase of MS,”